Regenerative Medicine in the Bronze Age: MSCs and MSC-EVs Leading the Way

Regenerative medicine is experiencing a growing interest in the Bronze Age, with mesenchymal stem cells (MSCs) and their extracellular vesicles (MSC-EVs) at the forefront. Despite strong biological potential, translating MSC therapies remains challenging due to difficulties in demonstrating efficacy and consistency. Biomarker-driven trials are essential for targeting autoimmune diseases like progressive multiple sclerosis.

MSCs are appealing for allogeneic therapies, as they can be cryopreserved and used off-the-shelf for larger patient populations. Moving from 2D to 3D culture systems can impact confluency, marker profiles, and EV productivity, necessitating optimization of media, serum, and reagents to maintain critical quality attributes. As 3D systems advance, the industry demands more chemically defined, serum-free solutions for clinical development.

MSC-EVs are gaining attention as a novel therapeutic solution, with over 500 MSC-derived EV clinical trials underway. However, their classification, safety, efficacy, scale-up, and commercialization remain uncertain, placing them in a regulatory grey zone. Regulators are likely to focus on process consistency, EV identity, and release testing in later-stage development.

Developers must address early the impact of GMP processes and reagents on EV outputs to maintain consistency and clarify efficacy, purity, and consistency priorities.